Skip to main content
NIH funding notice RFA-AG-23-008

Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required)

Closed on June 15, 2022.

Posted
January 5, 2022
Close date
June 15, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
1
1 new
First-year cost
$618,218
Institutions
1
1 contact PI

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. UNIVERSITY OF WISCONSIN-MADISON1

Most frequent study sections

  1. Special Emphasis Panel (ZAG1 ZIJ-P (J1))1
1 award under RFA-AG-23-008 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2023Safer mTOR inhibition for human geroprotection1U01AG081482-01Konopka, Adam RLamming, Dudley WilliamUNIVERSITY OF WISCONSIN-MADISON, WIFirst-year cost $618,218Study section ZAG1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-AG-23-008: Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required) | ScienceDex | ConductScience